nasdaqregn
Shares of Sanofi were up 10.20% the week ended March 24, while Regeneron finished with a gain of 9.68%, following promising news about the company’s jointly developed medication Dupixent.Clinical trial results showed the drug reduced severe flare-ups of COPD at a far better rate than a placebo.There are currently no equivalent treatments for COPD, meaning the drug has blockbuster potential, once approved.Analysts expect Dupixent sales to total $20 billion by the end of the decade.Wall Street has boosted price targets for both companies.5 stocks we like better than SanofiQ4 2022 hedge fund lett...
ValueWalk
Pfizer Inc. could outperform with consistent dividend and revenue growth.Regeneron Pharmaceuticals Inc. has a high P/E with a low upside but value could increase on continued revenue growth.Innoviva Inc. started the year heavily down but strong revenue gains could offset projected losses.Exelixis Inc. is near its 52-week bottom but a furtive P/E and impressive upside could push it to a 52-week high.5 stocks we like better than ExelixisQ4 2022 hedge fund letters, conferences and more Find A Qualified Financial AdvisorEach advisor has been vetted by SmartAsset and is held to a fiduciary standard...
ValueWalk
Brilliant Biotech Plays to Consider Adding NowWhile the idea of adding exposure to one of the most volatile sectors of the market during a correction might not sound great on paper, the truth is that investors should view the biotech sector as a sleeping giant that could be ready to wake up in the coming weeks. Many of the strongest biotech companies can make for great core holdings in your portfolio thanks to a combination of strong drugs that generate stable cash flows and high upside novel drugs in development that have the potential to become huge winners. Q4 2021 hedge fund letters, confe...
ValueWalk
Following is the unofficial transcript of a CNBC interview with Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Co-Founder & CEO Dr. Leonard Schleifer on CNBC’s “Squawk Box” (M-F, 6AM-9AM ET) today, Thursday, December 16. Following is a link to video on CNBC.com: Q3 2021 hedge fund letters, conferences and more Regeneron CEO: We’ll Need Covid Antibodies To Work Against Omicron If It SurgesMEG TIRRELL: Becky, thanks so much. Regeneron just a few moments ago saying its antibody drug used to treat patients with COVID loses potency against the Omicron variant. Dr. Len Schleifer is the CEO of Regeneron...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら